X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Merck Ltd with Elder Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MERCK LTD vs ELDER PHARMA - Comparison Results

MERCK LTD    Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    MERCK LTD ELDER PHARMA MERCK LTD/
ELDER PHARMA
 
P/E (TTM) x 50.3 -0.2 - View Chart
P/BV x 7.6 0.1 7,523.1% View Chart
Dividend Yield % 0.4 0.0 -  

Financials

 MERCK LTD   ELDER PHARMA
EQUITY SHARE DATA
    MERCK LTD
Dec-16
ELDER PHARMA
Jun-14
MERCK LTD/
ELDER PHARMA
5-Yr Chart
Click to enlarge
High Rs1,060380 278.9%   
Low Rs623188 331.4%   
Sales per share (Unadj.) Rs632.4491.2 128.8%  
Earnings per share (Unadj.) Rs45.7-3.2 -1,436.9%  
Cash flow per share (Unadj.) Rs62.314.4 432.5%  
Dividends per share (Unadj.) Rs11.000-  
Dividend yield (eoy) %1.30-  
Book value per share (Unadj.) Rs388.8376.5 103.3%  
Shares outstanding (eoy) m16.6020.54 80.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.30.6 230.1%   
Avg P/E ratio x18.4-89.3 -20.6%  
P/CF ratio (eoy) x13.519.7 68.5%  
Price / Book Value ratio x2.20.8 286.9%  
Dividend payout %24.10-   
Avg Mkt Cap Rs m13,9695,833 239.5%   
No. of employees `0001.6NA-   
Total wages/salary Rs m1,4872,179 68.2%   
Avg. sales/employee Rs Th6,631.9NM-  
Avg. wages/employee Rs Th939.2NM-  
Avg. net profit/employee Rs Th479.4NM-  
INCOME DATA
Net Sales Rs m10,49810,089 104.1%  
Other income Rs m242257 94.5%   
Total revenues Rs m10,74110,346 103.8%   
Gross profit Rs m1,135-792 -143.4%  
Depreciation Rs m276361 76.3%   
Interest Rs m02,756 0.0%   
Profit before tax Rs m1,102-3,653 -30.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m03,713 0.0%   
Tax Rs m343125 274.3%   
Profit after tax Rs m759-65 -1,161.3%  
Gross profit margin %10.8-7.8 -137.8%  
Effective tax rate %31.1-3.4 -909.1%   
Net profit margin %7.2-0.6 -1,116.0%  
BALANCE SHEET DATA
Current assets Rs m6,4109,240 69.4%   
Current liabilities Rs m8,8289,998 88.3%   
Net working cap to sales %-23.0-7.5 306.8%  
Current ratio x0.70.9 78.6%  
Inventory Days Days5846 124.6%  
Debtors Days Days3860 64.0%  
Net fixed assets Rs m1,40610,124 13.9%   
Share capital Rs m166206 80.7%   
"Free" reserves Rs m6,2865,582 112.6%   
Net worth Rs m6,4557,734 83.5%   
Long term debt Rs m04,889 0.0%   
Total assets Rs m8,82822,882 38.6%  
Interest coverage xNM-0.3-  
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x1.20.4 269.7%   
Return on assets %8.611.8 73.1%  
Return on equity %11.8-0.8 -1,391.4%  
Return on capital %17.122.3 76.5%  
Exports to sales %8.33.0 272.5%   
Imports to sales %21.00.4 4,925.9%   
Exports (fob) Rs m869307 283.6%   
Imports (cif) Rs m2,20943 5,125.8%   
Fx inflow Rs m959307 312.7%   
Fx outflow Rs m2,612125 2,084.6%   
Net fx Rs m-1,653181 -911.9%   
CASH FLOW
From Operations Rs m1,07011,754 9.1%  
From Investments Rs m-750-561 133.8%  
From Financial Activity Rs m-150-6,762 2.2%  
Net Cashflow Rs m1714,432 3.9%  

Share Holding

Indian Promoters % 0.0 39.6 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 7.5 242.7%  
FIIs % 1.0 16.8 6.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 36.1 80.6%  
Shareholders   28,591 16,479 173.5%  
Pledged promoter(s) holding % 0.0 77.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare MERCK LTD With:   DR. REDDYS LAB  STERLING BIOTECH  ASTRAZENECA PHARMA  VENUS REMEDIES  IPCA LABS  

Compare MERCK LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 383 Points Lower; Realty and Auto Stocks Drag(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

MERCK LTD Announces Quarterly Results (1QFY19); Net Profit Up 63.1% (Quarterly Result Update)

Aug 8, 2018 | Updated on Aug 8, 2018

For the quarter ended June 2018, MERCK LTD has posted a net profit of Rs 328 m (up 63.1% YoY). Sales on the other hand came in at Rs 2 bn (down 17.1% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

MERCK LTD Announces Quarterly Results (4QFY18); Net Profit Up 53.2% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, MERCK LTD has posted a net profit of Rs 227 m (up 53.2% YoY). Sales on the other hand came in at Rs 3 bn (up 27.1% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Don't Panic in This Falling Market... Do This Instead(The 5 Minute Wrapup)

Oct 5, 2018

Find companies with long term durable moats, which are correcting with the current broader market sell-off.

Taxpayers to pay salaries of CEOs/CIOs of Mutual Funds(The Honest Truth)

Oct 5, 2018

Ajit Dayal on the crisis in the market and in the mutual fund industry.

This Market Crash could be the Biggest Wealth Creating Opportunity Since 2008(Profit Hunter)

Oct 8, 2018

While widespread fear is the friend of a value investor, serving up bargain purchases; personal fear is an investor's biggest enemy.

IPO Market Feels the Heat of the Market Crash(Sector Info)

Oct 12, 2018

The sentiments in primary market have also deteriorated amid the stock market correction. Most listed IPOs of 2018 are trading below their issue price.

Are These Deep Corrections a Buying Signal?(Chart Of The Day)

Oct 5, 2018

The correction has bought many good companies to reasonable valuations. Go against the wisdom of crowd and Buy.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MERCK LTD SHARE PRICE


Oct 17, 2018 (Close)

TRACK MERCK LTD

  • Track your investment in MERCK LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MERCK LTD - ALEMBIC PHARMA COMPARISON

COMPARE MERCK LTD WITH

MARKET STATS